Champions Oncology (CSBR) risk factors, FY2025 10-K

Other

1. 01We historically incurred losses from operating activities, may require significant capital and may never achieve sustained profitability
2. 02Currently, the Company derives revenue primarily from research services, while pursuing efforts to further develop our drug discovery business units
3. 03We may incur greater costs than anticipated, which could result in sustained losses
4. 04We may not be able to implement our business strategies, which could impair our ability to continue operations
5. 05Our laboratories are subject to regulation and licensure requirements, and the healthcare industry is highly regulated; we may face substantial penalties, and our business activities may be impacted, if we fail to comply
6. 06If our laboratory facilities are damaged or destroyed, or we have a dispute with one of our landlords, our business would be negatively affected
7. 07Any health crisis impacting our colony of laboratory mice could have a negative impact on our business
8. 08We have limited experience marketing and selling our products and may need to rely on third parties to successfully market and sell our products and generate revenues
9. 09We will continue to be dependent upon key employees
10. 10Because our industry is very competitive and many of our competitors have substantially greater capital resources and more experience in research and development, we may not succeed in selling or increasing sales of our products and technologies
11. 11If we are unable to protect our intellectual property, we may not be able to compete as effectively
12. 12If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
13. 13Claims by others that our products infringe their patents or other intellectual property rights could adversely affect our financial condition
14. 14Research service studies are subject to cancellation based on changes in customer’s development plans
15. 15We face competition in the life science market for computational software and for bioinformatics products
16. 16Drug development programs, particularly those in early stages of development, may never be commercialized
17. 17Impairment of goodwill may adversely impact future results of operations
18. 18Our ability to use our net operating loss carry-forwards and certain other tax attributes may be limited
19. 19We have a limited market for our common stock, which makes our securities very speculative
20. 20Investment in our common stock may be diluted if we issue additional shares in the future
21. 21Potential future sales or issuances of our common stock to raise capital, or the perception that such sales could occur, could cause dilution to our current stockholders and the price of our common stock to fall
22. 22Our stock price is volatile and therefore investors may not be able to sell their common stock at or above the price they paid for it
23. 23Certain provisions of our charter and bylaws and of our contractual agreements contain provisions that could delay and discourage takeover attempts and any attempts to replace our current management by stockholders
24. 24Certain provisions of Delaware law make it more difficult for a third party to acquire us and make a takeover more difficult to complete, even if such a transaction were in the stockholders’ interest
25. 25Our management and four significant stockholders collectively own a substantial majority of our common stock
26. 26We have not paid any cash dividends in the past and have no plans to issue cash dividends in the future, which could cause the value of our common stock to have a lower value than other similar companies which do pay cash dividends
27. 27If securities or industry analysts do not publish or cease publishing research or reports about us, our business or our market, or if they change their recommendations regarding our common stock adversely, the price of our common stock and trading volume could decline
28. 28Our business operations could be disrupted if our information technology systems fail to perform adequately
29. 29A pandemic, epidemic, or outbreak of an infectious disease in the United States or elsewhere may adversely affect our business and we are unable to predict the potential impact
30. 30Deterioration in general economic conditions in the United States and globally, including the effect of prolonged periods of inflation on our customers and suppliers, could harm our business and results of operations
31. 31Our Chief Executive Officer resides in Israel and we have several customers with their operations located in Israel, and, therefore, our leadership continuity and results may be adversely affected by political, economic, and military instability in Israel